1,968 trials (keyword fallback)
EBV-Related Post-Transplant Lymphoproliferative Disorder · Monomorphic Post-Transplant Lymphoproliferative Disorder · Polymorphic Post-Transplant Lymphoproliferative Disorder
Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…
Relapsed or Refractory Lymphoproliferative Malignancies · Hodgkin's Lymphoma · Peripheral T-cell Lymphoma
Primary: Objective Responses Assessed by International Workshop Criteria (IWC) — 8; 5; 7 participants
Lymphoproliferative Disorder
Primary: Event-free Survival — 71 percentage of participants analyzed
Recurrent Lymphoproliferative Disorder · Refractory Lymphoproliferative Disorder
Primary: Overall Response Rate — 0 percentage of participants
Hematologic Neoplasms
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation — 3; 9; 5; 19 Participants
Neoplasms
Primary: Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) — 1; 1; 1; 5 Participants
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 63.6; 50.0; 0; 43.5 Percentage of participants
Recurrent Grade 1 Follicular Lymphoma · Recurrent Grade 2 Follicular Lymphoma · Recurrent Grade 3 Follicular Lymphoma
Primary: Response Rate — 11; 6 participants
ALPS · Hypersplenism · Lymphadenopathy
Primary: Number of Participants With Response — 0 participants
High Risk Neuroblastoma · Recurrent Neuroblastoma · Recurrent Osteosarcoma
Primary: Percent (95% CI) of Participants With Grade 3 or Higher Adverse Events (Dose Finding Cohort) — 71.4; 100 percentage of participants
Refractory Plasma Cell Myeloma · Recurrent Plasma Cell Myeloma
Primary: Number of Patients With Dose-Limiting Toxicities (Phase I) — 1; 1 Participants
Malignant Solid Tumor - Malignant Nervous System Neoplasm
Primary: Phase 1: Maximum Tolerated Dose of Cabazitaxel — 30 mg/m^2
Leukemia
Primary: Maximum Tolerated Dose (MTD) Oxaliplatin — 25 mg/m^2
Cutaneous T-Cell Lymphoma · Mature T-cell Malignancies · Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 20 mg/day
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 68.0; 50.0; 16.0; 14.3 Percentage of participants